Tislelizumab Combined With Chemotherapy in Patients With TKI-Resistant EGFR-Mutated Non-squamous NSCLC
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
A phase II, open-label, multicenter, single-arm, prospective clinical study to investigate
the efficacy and safety of tislelizumab (anti-pd1 antibody) combined with chemotherapy in
non-squamous non-small cell lung cancer patients with EGFR sensitizing mutation who failed
EGFR TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) therapy.